Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Volitionrx Ltd

NYSE: VNRX · Life Sciences · 7 alerts · CIK 93314

Share price
$0.1998Close, Nov 16
Market cap
$7.21M
Shares outstanding
36.08MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Volitionrx Ltd filings on SEC EDGAR ↗

4:21 PM ET 10-Q
Financial Results

Volitionrx Q3 2026 Results: Net Loss of $3.8M, Loss Narrows

VolitionRx reported total revenues of $3.0 million for the nine months ended September 30, 2026, a significant increase from $1.3 million in the prior year, primarily driven by product sales. Despite higher revenues, the company recorded a net loss of $17.8 million for the period, impacted by $15.9 million in operating expenses and $5.0 million in other expenses including debt extinguishment costs.

Key figure
Net loss $3.8M
4:16 PM ET 8-K
Financial Results

Volitionrx Financial Results

VolitionRx reported financial results for the third quarter of 2026, highlighting progress in its Nu.Q platform across sepsis, lung cancer, and veterinary diagnostics. The company noted the launch of the French government-funded DETECSEPS program and active licensing discussions for its Capture-Seq technology in the liquid biopsy market.

Term
Q3 2026

“It has been a very full quarter as we have continued to execute our plan to commercialize our game-changing Nu.Q® platform. We have made strong progress across our key product pillars this year, evidencing clinical utility across a broad spectrum of indications whilst driving commercialization and licensing efforts worldwide. At the same time, we have taken decisive action to strengthen our financial profile by cutting costs and significantly reducing convertible note debt.”

Cameron Reynolds, President and Group Chief Executive Officer
8:31 AM ET 8-K
Executive Compensation

Volitionrx Executive Compensation

VolitionRx CEO Cameron Reynolds agreed to a further temporary reduction in his annual base salary from $355,456 to $236,970.50 as part of the company's cost-reduction measures. This follows a previous 25% reduction effective February 2026, bringing his total salary down from a contractual base of $473,941. The reduction will remain in effect until the Compensation Committee determines the company's financial stability is secured, potentially following a significant licensing or commercial agreement.

Term
temporary
5:01 PM ET 8-K
Loan & Debt

Volitionrx $500K Debt Financing with Lind Global Asset Management XII LLC

VolitionRx entered into a waiver and consent agreement with Lind Global Asset Management to make a $500,000 partial cash prepayment on a senior secured convertible promissory note, reducing the outstanding balance to approximately $0.7 million. The agreement also defers monthly repayments for November and December 2026 and pauses Lind's conversion rights until January 1, 2027, unless the stock price reaches $0.275.

Value
$500K
Counterparty
Lind Global Asset Management XII LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.